Background/Aims: To investigate the cardioprotective effects of intravenous immunoglobulins (IVIG) in rats subjected to regional myocardial ischemia reperfusion (I/R). Methods: Langendorff-perfused rat hearts were used in this study. Hearts subjected to regional ischemia served as a negative untreated control. The effects of IVIG pre-and post-ischemic treatment on left ventricular function, coronary vascular dynamics and contractility were assessed. IVIG were administered in either a low or high dose. The infarct size was determined using triphenyltetrazolium chloride and through biochemical assays using the measured creatine kinase and lactate dehydrogenase levels. Apoptosis was evaluated by the TUNEL assay, and the caspase-3 expression level was assessed by immunoblotting. The cytokine levels were measured by ELISA. Results: Low and high doses of immunoglobulins administered 2 hours before sacrifice, before the ischemic insult or at reperfusion resulted in a significant improvement in cardiac hemodynamics, coronary vascular dynamics and heart contractility. A significant decrease in the infarct size and cardiac enzymes was also evident compared to those in the control. IVIG administered as an infusion at reperfusion or pre-treatment resulted in a marked decrease in myocyte apoptosis, which was associated with decreased levels of caspase-3 expression in the supernatants of homogenized left ventricles. Infusion of IVIG both pre-ischemia and at reperfusion did not show the same protective effects. Conclusions: This study demonstrates a novel protection to the heart by low and high doses of IVIG given either pre-or post-ischemia.
Fig. 1. Schematic representation showing the study protocol.
A: sham, only canulation, stabilization and perfusion for 1 hour, B: Control, only ischemia, C: Ischemia and IVIG, D: Ischemia and IVIG infusion 2 hrs before sacrifice, E: IVIG infused 5 min before reperfusion and continued for 10 minutes after the start of reperfusion and F: IVIG infused 15 min before ischemia and 5 min before reperfusion and continued for 10 minutes thereafter.
The heart was instrumented with pacing electrodes on the right atrial (RA) appendage. The left descending coronary artery was encircled with a snare at approximately 0.5 cm below the atrioventricular groove, and a small rigid plastic tube was positioned between the heart and the snare to ensure complete occlusion of the coronary artery. The aorta was cannulated, allowing retrograde perfusion of the heart with a preload of 6 mm Hg. The preload was kept constant under basal-control conditions.
Study protocol
The present study investigated the role of pre-and post-treatments with immunoglobulins (Gamunex ® -C; Grifols Therapeutics Inc, NC, USA) or the combination thereof on the protection of the heart against I/R injury ( Fig. 1) .
For the pre-treatment protocol, the subjects were subdivided into 4 groups. In group A, the sham hearts (n = 6) were cannulated, and a thread was passed below the coronary artery with no further treatment. In group B, control hearts (n = 6) were subjected to I/R without any further treatment. In group C, either low dose IVIG (IgL) (0.6 g/kg) or high dose IVIG (IgH) (1 g/kg) (n = 6 each) was infused in the buffer following the stabilization period at 15 min before the index ischemia. In group D, the rats (n = 6 each) were intravenously infused with either IgL or IgH 2 hrs before sacrifice and heart isolation ( Fig. 1) .
For the post-treatment experiments, the hearts of untreated rats were isolated. The hearts in treatment group E were treated with either IgL or IgH (n = 6 each) 5 min before reperfusion, and the treatment was continued for 10 minutes after the start of reperfusion. The hearts in the combined treatment group F were treated with either IgL or IgH in the buffer 15 min before ischemia and 5 min before reperfusion, and the treatment was continued for 10 minutes thereafter (n = 6 each). In all hearts, the ischemia was produced by 30 min of coronary artery occlusion (CAO), followed by 30 min of reperfusion.
Hemodynamic evaluations
Coronary flow (CF) was measured continuously by an electromagnetic flow probe attached to the inflow of the aortic cannula. The probe was attached to a flow meter, which was interfaced to a personal computer. The CF in mL/min was continuously monitored by timed collection of the coronary effluent, and computations were performed. The coronary vascular resistance (CVR) was computed every 10 seconds along with the hemodynamic data by an on-line data acquisition program (Isoheart software V 1.524-S, Hugo-Sachs Electronik, Germany). The left ventricular developed pressure (DPmax) and left ventricular end diastolic pressure (LVEDP) were measured by placing and securing a water-filled latex balloon in the left ventricular cavity. The balloon was attached to a pressure transducer, and the DC-Bridge amplifier (DC-BA) of the pressure module (DC-BA type 660, Hugo-Sachs Electronik, Germany) interfaced to a personal computer for on-line monitoring of the left ventricular pressure and its derivatives. The left ventricular DPmax was derived from the online acquisition of left ventricular systolic pressure (LVSP) by the Max-Min module. This module converts the output from the DC-BA to DPmax by subtracting LVEDP from the maximal LVSP. 
Cardiac damage assessment via infarct size and cardiac enzymes
Although the risk area can be perfectly evaluated using real-time myocardial contrast echocardiography (MCE) [29] , this study used the triphenyltetrazolium chloride (TTC) method and cardiac enzymes level, which fit better in our ex vivo study. Infarct size was determined by the TTC method. Hearts were collected after 30 min of reperfusion and stored overnight at -20 °C. The next day, the hearts were cut into 4-5 pieces from apex to base, incubated in TTC (1%) solution in isotonic pH 7.4 phosphate buffer and then fixed with formaldehyde (4%). Images were taken using a Nikon camera. The pale red, unstained areas of every slice were marked manually on the image, and the corresponding areas and were quantified using Leica ImageJ (ImageJ, Wayne Rasb and National Institute of Health, USA). The ratio of infarct size to LV area was calculated and expressed as a percentage for every heart. Cardiomyocyte injury was evaluated by measuring the cardiac enzyme, creatine kinase (CK) and lactate dehydrogenase (LDH) levels in the coronary effluent during the reperfusion period, as described previously [30] .
Assessment of apoptosis: terminal deoxynucleotidyl transferase mediated UTP nick end labeling (TUNEL assay)
Three-micrometer thick paraffin sections were de-waxed by submersion in xylene, rehydrated by passing through descending grades of alcohol (100-70% alcohol), washed with distilled water and PBS, immersed in antigen retrieval solution (sodium citrate buffer: a mixer of 13.5 ml of solution A (21 g citric acid monohydrate in 1 L distilled water) + 61.5 ml of solution B (29.4 g sodium citrate dehydrate in 1 L distilled water) with distilled water for the remained of the 750 ml volume) for 5 min in a microwave oven at medium power. Tissue sections were brought to room temperature, kept in PBS for 5 min, in triton X (0.1% in PBS, Triton-Sigma-Aldrich, 234729) for 8 min and washed twice with PBS. Fifty microliters of TUNEL reaction mixture (50 µl of enzyme solution (terminal deoxynucleotidyl transferase from calf thymus (EC 2.7.7.31) in storage buffer) and 450 µl of labeling solution (nucleotide in reaction buffer)) was added to the section until the whole tissue was covered. The negative control section was covered with only 50 µl of labeling solution. The slides were incubated in humidified chamber for 1 hour at 37 o C and rinsed thrice in PBS. Next, freshly prepared DAPI (4' 6-diamidino-2-phenylindole, 1:4000, Sigma Chemicals, D9542) was added to the tissue section for 1 min, and the sections were mounted in Vectashield (Vector Laboratories; CA-94010). The edges of the cover slips were sealed with nail polish. The slides were examined using a confocal microscope, and selected areas were photographed. Ten fields/heart were examined, the nuclei of TUNEL-positive myocytes were counted, and the mean values were calculated. An In situ Cell Death Detection Fluorescein kit (Roche) was used for this purpose.
Immunoblotting
Left ventricles (n = 4 per group) were homogenized in ice-cold lysis buffer, and the homogenate was centrifuged at 4000 rpm for 10 min. The supernatant was collected, the protein content was measured, and the samples were aliquoted and stored at -80°C for further analysis. The expression of the evaluated proteins was determined as described previously [31] . Equal loading was checked by stripping the membrane and reprobing with actin antibodies. The total caspase-3 level was determined using monoclonal antibodies (Cell Signaling Technology, Inc). Detection was performed using enhanced chemiluminescence after incubation with a suitable secondary antibody conjugated to horseradish peroxidase (ECL; Cell Signaling Technology). Densitometric analysis was performed using Quantity One software (BioRad).
Pro-inflammatory cytokine testing
Left ventricular tissues were homogenized in ice-cold lysis buffer, and the homogenate was centrifuged at 4000 rpm for 10 min. The supernatant was removed, and the protein content was measured. Dilution was performed as required by manufacturers' guidelines. The expression of pro-inflammatory cytokines [TNF-alpha (TNF-α), interleukin 1 (IL-1) and interleukin 6 (IL-6)] were determined by ELISA. The detection procedures for each of the proteins were performed according to the guidelines of the manufacturers of the respective commercial kits. The titers of IL-1, IL-6 and TNF-a in cardiac muscle samples were used. The rat IL-1, IL-6 and TNF-a kits were obtained from Biosource International, USA.
Sample storage
All samples were immediately frozen in liquid nitrogen and subsequently stored at -80°C. cardio-protective effects by means of LV function and coronary-vascular-dynamics. This is in contrast to either pre-or post-treatment given alone. The pre-treatment protocol shown was done using IVIG infusion in the buffer. *P< 0.01 compared to respective controls and † P< 0.01 compared to ischemic period for IVIG at reperfusion (IgH/R and IgL/R).
Statistical analysis
All data are presented as the mean ± SE. One-way analysis of variance (ANOVA) for repeated measures within each group and between groups was performed on absolute values, even when presented as % of baseline. Only in cases when this analysis showed a significant difference, post hoc analysis was used for 
Results

Hemodynamic effects of IVIG
The heart hemodynamics, contractility and coronary vascular dynamics changed in sham animals; however, the changes in these parameters were not statistically significant throughout the protocol period. Induction of ischemia resulted in a significant (P<0.01) worsening in the heart and coronary vascular dynamics compared to those in the sham hearts. Interestingly, both low and high doses of IVIG treatment given 2 hours before animal sacrifice or preischemic insult significantly improved the left ventricular function by increasing DPmax and decreasing LVEDP compared to those of the respective controls (P < 0.05) (Fig. 2A) . Coronary vascular dynamics were also positively affected, as shown by the significant increase in CF and decrease in CVR compared to those of the respective controls (P < 0.05) (Fig. 2A) . Compared to the respective controls, IVIG treatment normalized the myocardial contractility, as assessed by +dP/dt and -dP/ dt (P< 0.05) ( Table 1 ). Similar effects were achieved when IVIG were administered at reperfusion (Fig. 2B and Table   Table 1 . Effects of IVIG treatment protocols on post-ischemic recovery of left ventricular contractility (+dP/dt and -dP/dt). ¶ Mean ± SE, * P< 0.01 and ** P< 0.05 compared to respective controls, ƚ P< 0.001 and ƚƚ P< 0.01 compared to ischemic period for IVIG, IgL: low dose immunoglobulin (0.6g/kg); IgH: high dose immunoglobulin (1g/kg); R: reperfusion; IV: intravenously; P: pretreatment (15 min before ischemia) Fig. 3 . Infarct size after IVIG treatment protocols. IVIG as pretreatment or at reperfusion decreased infarct size while combined pre-and post-treatment with IVIG showed no differences in the infarct size compared to the control group. Top: representative 2,3,5-triphenyl-2H-tetrazolium chloride-stained heart slices from the apex to base. Bottom, measured infarct size, normalized to the LV area, in isolated rat hearts at the end of reperfusion. Ctr: control; IgL: low dose immunoglobulin (0.6g/kg); IgH: high dose immunoglobulin (1g/kg); R: reperfusion; IV: intravenously; P: pretreatment (15 min before ischemia). *P< 0.001 compared to respective controls. 1) . Surprisingly, the combination of immunoglobulin treatments pre-and post-ischemia showed no cardioprotective effects (Fig. 2C and Table 1 ). The recovery values shown in all hearts and cardiovascular parameters were comparable to the sham group values (Fig. 2) .
Infarct size
Immunoglobulin (low or high dose) infusion at reperfusion caused a significant reduction in infarct size compared to that of the respective controls (P < 0.001) (Fig 3) . Similar effects were found when IVIG were given during the pre-ischemia treatment protocols with either dose in the buffer 15 min before the index ischemia or when IVIG were infused intravenously 2 hrs before the rat sacrifice and heart isolation. However, the combined preand post-ischemia treatments with IVIG showed no improvement in the infarct size compared to that of the control group.
Cardiac enzymes
For both doses of IVIG, administration post-treatment at reperfusion or pretreatment either infused in the buffer 15 min before the index ischemia or via intravenous injection 2 hrs before the rat sacrifice resulted in a significant decrease in the cardiac enzymes LDH and CK compared to those of the respective controls. This effect was completely abrogated when IVIG were administered both pre-and post-treatment (Table 2) .
IVIG effects on cardiomyocyte survival IVIG administration at reperfusion or pre-ischemic treatment either dosed in the buffer following the stabilization period 15 min before the index ischemia or infused intravenously 2 hrs before sacrificing the rats and heart isolation either in low or high doses resulted in a marked decrease in myocytes apoptosis (P<0.01) (Fig. 4) . This effect was smaller when IVIG were administered both pre-and post-ischemic treatment. These results were confirmed by the caspase-3 expression levels (Fig. 5) .
Pro-inflammatory cytokines
All IVIG treatment protocols resulted in a significant increase in the L-1 and IL-6 levels in the cardiac muscle samples. However, the TNF-α expression level did not increase (Fig. 6) . Table 2 . Effects of various IVIG treatments on heart enzymes levels, * Mean ± SE, ¶ P-value compared to respective controls, IgL: low dose immunoglobulin (0.6g/kg); IgH: high dose immunoglobulin (1g/kg); R: reperfusion; IV: intravenously; P: pretreatment (15 min before ischemia) Table 2 . Effects of various IVIG treatments on heart enzymes levels, * Mean ± SE, ¶ P-val controls, IgL: low dose immunoglobulin (0.6g/kg); IgH: high dose immunoglobulin (1g intravenously; P: pretreatment ( 
Discussion
In the current study, IVIG showed significant cardioprotective effects in rat hearts subjected to regional myocardial ischemia when applied before or after the ischemic insult; the effects were assessed using hemodynamic evaluation, infarct size and cardiac enzymes.
Several therapeutic interventions were reported as protective procedures against myocardial I/R injury. However, it is too soon for some of these procedures to be used in clinical practice [32] [33] [34] [35] . Other procedures showed disappointing results when were translated to the clinic [36] [37] [38] . Ischemic preconditioning (repetitive ischemic episodes before the insult) was proposed in attempt to decrease I/R injury [39] . Although this method showed considerable heart protection [28, 40, 41] , the likelihood of its use in clinical application is rather limited because of the unexpectedness of most ischemic events. More applicable in clinical practice is ischemic postconditioning (repetitive ischemia at the onset of reperfusion) [42] . Indeed, this method showed pronounced heart protection, but its application in the clinic is still questionable because of the potential damage to coronary blood vessels. Given the safety profile of IVIG and its being protective shortly before reperfusion, IVIG seem to be an attractive possibility for patients undergoing reperfusion post-myocardial infarction. In a recent study, Gullestad et al. administered IVIG as induction therapy to acute myocardial infarction patients suffering a depressed left ventricular ejection fraction (LVEF) after they were treated by percutaneous coronary intervention and thereafter as monthly infusions for 26 weeks [43] . Compared to placebo, IVIG did not improve myocardial function, left ventricle remodeling or infarct size during follow-up. A major limitation of this study is that the study only included a small number of patients who had depressed left ventricle function. The study also evaluated few markers as primary endpoints. Many other parameters other than LVEF, such as duration of stay in intensive care units and rate of complications (e.g., arrhythmias, cardiogenic shock, recurrent myocardial infarction, unstable angina, hospitalization and mortality), should be considered when evaluating the effects of this regimen in future clinical trials. Moreover, the cumulative IVIG dose during the induction therapy was 2 g/kg, which is relatively high and could be responsible for the absence of the protective effects; this absence was similar to our study, where no cardioprotective effects were found in the combined IgL and IgH treatment group. Additionally, we are not sure whether the IVIG treatment in the Gullestad study was provided before or a few hours after reperfusion, whereas in our study, IVIG were beneficial when administered a few minutes before reperfusion.
Modulation of apoptosis and cell death is a well-known anti-inflammatory effect of IVIG [19] . These effects result from several mechanisms, such as suppression of NLRP1 and NLRP3 inflammasome activity, anti-Fas effects, inhibition of the caspase-3, caspase-8 and caspase-9 cascades, modulation of BCR signaling and inhibition of complement-mediated apoptosis [26, [44] [45] [46] [47] . Furthermore, other immunomodulatory effects of IVIG may have played a role in this cardioprotective effect, so further studies are needed to better understand these mechanisms. However, more studies are also needed to understand the lack of protection demonstrated by the pre-and post-IVIG combination. We anticipate that this lack of protection could be due to the high IVIG dose. Combining two protocols of IVIG before ischemia and at reperfusion might have resulted in a dose higher than the threshold required for protection and may activate specific molecules that offset the IVIG-induced protection. This result could also be related to the duration of IVIG infusion, as the duration of the protective procedure has been proven to be essential for the outcome. Longer episodes were previously proven to offset the protective effect in some studies [48] . Pharmacological interventions that span the ischemic period were also found to impact the ischemic event and block the expected protection [49] . This scenario might be applicable in the combination of preand post-ischemic IVIG treatments. Further studies are required to Fig. 6 . Pro-inflammatory cytokines levels in the cardiac muscle samples after IVIG infusion compared to the control group. IVIG increased IL-1 (A) and IL-6 (B) while it did not affect TNF-α levels. Ctr: control; IgL: low dose immunoglobulin (0.6g/ kg); IgH: high dose immunoglobulin (1g/ kg); R: reperfusion; IV: intravenously; P: pretreatment (15 min before ischemia). *P<0.05, ¥P<0.01, ¶P<0.001 compared to the respective control.
resolve this controversy before testing this regimen in the clinic.
Decreasing the levels of pro-inflammatory cytokines was found to be crucial for the protection against tissue damage induced by cardiac I/R [40, 50, 51] . Interestingly, the IVIG treatment in the current study not only exerted protective effects against I/R injury but also resulted in an increase in IL-1 and IL-6 levels but not TNF-α levels. These findings are in line with previous studies in which IVIG infusion resulted in a significant increase in the proinflammatory cytokine levels [52] [53] [54] . The presence of protective effects due to IVIG infusion in the presence of increased pro-inflammatory cytokine levels is in contrast to the previous findings and requires further investigations. IVIG may protect against I/R injury through pathways that bypass the potential harmful effects of these pro-inflammatory cytokines.
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